Pharmaceutical News and Articles

Comprehensive and up-to-date drug news for both consumers and healthcare professionals.

Heat-Related Deaths Keep Rising for Americans

Reversing a prior downward trend, searing summers have caused a sharp uptick in the numbers of Americans who die from heat-related causes, new data shows. A loo

Trans Kids More Often Turn to Teachers Than Parents for Help

Troubled transgender students are more likely to turn to school staff than their own parents for support, a new study finds. Trans teens feeling depressed and a

Most Americans Unprepared to Handle Opioid Overdoses

More than three in four people (77 percent) say they would not know how to respond if they saw someone having an opioid overdose, according to survey results fr

Pelvic Floor Yoga Not Superior for Women With Urinary Incontinence

A 12-week pelvic floor yoga program is not superior to a physical conditioning program for women with daily urinary incontinence, according to a study published

Risk for Dementia Similar With SGLT2 Inhibitors, Dulaglutide in T2DM

For older adults with type 2 diabetes, the risk for dementia seems similar with sodium-glucose cotransporter 2 (SGLT2) inhibitors and the glucagon-like peptide

Female Physicians Have Significantly Increased Suicide Rates

Compared with the general population, female physicians appear to have a significantly increased suicide rate ratio, according to a review published online Aug.

After Weighting, 3.6 Million Likely to Be Newly Eligible for Semaglutide

Increases in eligibility for semaglutide are discussed in a research letter published online Aug. 27 in the Annals of Internal Medicine.After the Semaglutide Ef

GSK Receives US FDA Breakthrough Therapy Designation for B7-H3-Targeted Antibody-Drug Conjugate GSK5764227 in Relapsed or Refractory Extensive-Stage Small-Cell Lung Cancer

GSK plc (LSE NYSE GSK) announced today that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for GSK5764227 (GSK 227), the

Tirzepatide Reduced the Risk of Developing Type 2 Diabetes by 94% in Adults with Pre-Diabetes and Obesity or Overweight

INDIANAPOLIS, Aug. 20, 2024. Eli Lilly and Company (NYSE LLY) announced today positive topline results from the SURMOUNT-1 three-year study (176-week treatment

Bayer Initiates Phase II Study of Soluble Guanylate Cyclase Activator (BAY3283142) in Patients with Chronic Kidney Disease

Berlin, Germany, August 22, 2024 Bayer announced today the start of the ALPINE-1 study, a Phase II clinical trial with BAY3283142, an investigational soluble gu

Popular Keywords